Almirall is a global biopharmaceutical company focused on skin health. We partner with healthcare professionals, applying Science to provide medical solutions to patients & future generations. Our R&D is focused on dermatology, with a wide range of programs including psoriasis, atopic dermatitis, actinic keratosis and acne. Founded in 1943 and headquartered in Barcelona, Almirall is listed on the Spanish Stock Exchange (ticker: ALM) and has become a key source of value creation for society thanks to its commitment to its principal shareholders and its decision to help others, understanding their challenges and seeking to improve their quality of life.
The Barcelona headquarters serves as the central hub for Almirall's global operations, including corporate management, strategic planning, research and development leadership, and global marketing.
State-of-the-art R&D laboratories and collaborative workspaces designed to foster innovation. The campus often reflects a commitment to sustainability and employee well-being.
A dynamic and patient-focused environment that encourages scientific curiosity, teamwork, and continuous learning. Emphasis on ethical practices and making a tangible difference in patients' lives.
Serves as the global nerve center for Almirall, driving strategic initiatives, R&D breakthroughs, and coordinating international operations. Its Barcelona location connects it to a vibrant pharmaceutical and biotech ecosystem.
Almirall has a direct presence in over 20 countries through subsidiaries and operates in over 70 countries through strategic agreements. Its global functions include research and development at multiple centers, manufacturing capabilities in Spain and Germany, and commercial operations across Europe, the USA, and other international markets. This widespread network supports the global launch and distribution of its specialized dermatology products.
Ronda General Mitre, 151
Barcelona
Catalonia
Spain
Address: Scholtzstraße 3, 21465 Reinbek, Germany
Serves as a key manufacturing plant (Hermal) for dermatological products and a commercial hub for Central Europe, driving market access and sales for Almirall's portfolio in the region.
Address: 505 Eagleview Blvd, Exton, PA 19341, USA
To expand Almirall's presence and deliver innovative dermatological treatments to patients in the U.S. market, managing all commercial and medical activities within the country.
Address: Tour Pacific, 11-13 Cr Valmy, 92800 Puteaux, Paris La Défense, France
To strengthen Almirall's market position in France, ensuring patient access to its dermatological solutions and engaging with the French healthcare community.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Almirall' leadership includes:
Almirall has been backed by several prominent investors over the years, including:
Almirall has experienced notable leadership transitions in the past year, including the resignation of its CEO and Chief Commercial Officer, the appointment of a new CFO, and the naming of an incoming CEO to take the helm in late 2024. The Chairman has also stepped in as interim CEO.
Discover the tools Almirall uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Almirall commonly uses the email format combining the first initial of an employee's first name with their full last name. This is a frequent pattern in many multinational corporations.
flastname@almirall.com
Format
jdoe@almirall.com
Example
85%
Success rate
Almirall Press Release • June 13, 2024
Almirall announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the marketing authorization of lebrikizumab for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate-to-severe atopic dermatitis, who are candidates for systemic therapy....more
Almirall Press Release • May 13, 2024
Almirall S.A. (ALM) announced its Q1 2024 financial results, highlighting strong performance with Core Net Sales reaching €247.4 MM, a 6.3% year-on-year increase, and Core EBITDA growing by 21% to €61.2 MM. The company reaffirmed its 2024 guidance....more
Almirall Press Release • May 6, 2024
Almirall announced the appointment of Volker Koscielny as its new Chief Executive Officer (CEO), effective September 1st, 2024. He will succeed Carlos Gallardo Piqué, who has served as interim CEO. Koscielny brings extensive experience from previous leadership roles in the pharmaceutical industry....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Almirall, are just a search away.